Catalent's fill-finish site in Bloomington, IN (credit: Catalent)

Up­dat­ed: No­vo Hold­ings pays $16.5B to take Catal­ent pri­vate — and sells three man­u­fac­tur­ing sites to No­vo Nordisk

No­vo Hold­ings, the in­vest­ment arm of No­vo Nordisk’s par­ent foun­da­tion, is buy­ing Catal­ent in a deal val­ued at $16.5 bil­lion, the biggest it’s ever made.

Catal­ent, a ma­jor play­er in the con­tract de­vel­op­ment and man­u­fac­tur­ing world, is heav­i­ly in­volved in pro­duc­ing No­vo Nordisk’s top-sell­ing obe­si­ty drug We­govy, which con­tin­ues to be in short­age. As part of the all-cash deal, No­vo Hold­ings will sell three Catal­ent fill-fin­ish sites and re­lat­ed as­sets to No­vo Nordisk in Italy, Bel­gium and Bloom­ing­ton, IN.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.